Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
|Articles|September 1, 2002
- Pharmaceutical Executive-09-01-2002
Dutch Government Just Says No
Author(s)Sarah Houlton
Spurred by concerns about rising drug expenditures, the Netherlands' government has introduced a list of "lifestyle" medicines that it intends to stop covering with its basic health insurance.
Advertisement
Spurred by concerns about rising drug expenditures, the Netherlands' government has introduced a list of "lifestyle" medicines that it intends to stop covering with its basic health insurance. It believes it should not have to pay for medi-cines for conditions brought on by unhealthy lifestyles, such as smoking and poor diet.
But plans to include cholesterol-reducing products on the list have worried the College voor Zorgverzekeringen (the Healthcare Insurance Board) which advises the government. The board has issued a report on statins, saying that their use should remain a part of basic health insurance because of their long-term preventive benefits.
Articles in this issue
about 24 years ago
Pharmaceutical Innovation Under Attackabout 24 years ago
More Statins = Fewer Heart Attacksabout 24 years ago
When Worlds Collideabout 24 years ago
Top European Trial Sponsorsabout 24 years ago
Novo Nordisk Cancels Clinical Trialsabout 24 years ago
Lilly Marketers Cross the Lineabout 24 years ago
Spending Hits a Wallabout 24 years ago
Strangers in the Shadowsabout 24 years ago
Plants and Patentsabout 24 years ago
Industry Audit & Companies of the YearAdvertisement
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
How Preventative Medications May Impact the Lingering Impact of COVID-19
4
Rebuilding Clinical Data Workflows for the AI Era
5